Phase II trial of induction mFOLFOX6 plus Avastin followed by neoaduvant chemoradiotherapy with TS-1 for MRI-defined high-risk rectal cancer (IMPACT-RC) - Phase II trial of induction mFOLFOX6 plus Avastin followed by neoadjuvant chemoradiotherapy with TS-1 for high-risk rectal cancer

The Cancer Institute Hospital of Japanese Foundation for Cancer Research0 个研究点目标入组 76 人开始时间: 2013年8月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Contraindication for either of S-1, Oxaliplatin, 5-FU, Leucovorin or Bevasizumab 2) Past history of severe hypersensitivity to the drugs 3) Past history of irradiation to the pelvis 4) Presence of infection with fever 5) Presence of severe morbidity such as heart failure, interstitial pneumonia, pulmonary fibrosis, uncontrollable diabetes, renal failure and liver failure. 6) Presence of sensory neuropathy 7) Presence or clinical manifestation of brain metastasis 8) Presence of diarrhea daily 9) Presence of ascites and/or pleural effusion which need aspiration 10) Presence of concomitant malignancy or past history of malignancy within five years 11) Female with pregnancy 12) Male who desire to keep fertility 13) Other inappropriate cases judged by doctors

发起方

The Cancer Institute Hospital of Japanese Foundation for Cancer Research